Gapping up
In reaction to earnings/guidance:

• LNN +3.4%

Other news:

• SSTK +3.6% (GETY and SSTK receive DOJ request for additional info on merger)
• SNY +3.3% (receives orphan drug designation in the US for two rare diseases with no approved medicines)
• NVS +2% (granted FDA accelerated approval for Vanrafia)
• PINE +1.6% (provides Q1 update)
• MESO +1.5% (files request for Type B meeting with FDA to discuss accelerated approval pathway for Revascor)
• SLND +1.3% (awarded two water resource projects)

Gapping down
(Briefing note - Due to the futures trading down 3-4%, most stocks are trading lower. The following represents stocks gapping down on known catalysts)

In reaction to earnings/guidance:

• RH -28.7%, FC -24.7%, RXST -24.2%, LSTR -5.2%, PENG -1.5%, AYI -1.3%

Select oil/gas related names showing early weakness:

• IWM -4.7%, QQQ -3.8%, SPY -3.3%, DIA -2.8%,

Other news:

• W -14.6% (in sympathy with RH earnings and downbeat guidance)
• WSM -10.3% (in sympathy with RH earnings and downbeat guidance)
• LZB -8.3% (in sympathy with RH earnings and downbeat guidance)
• LNW -7.6% (provides update on litigation; reaffirms 2025 targets)
• TOWN -7.3% (Towne Bank to acquire Old Point Financial Corporation)
• AAPL -7% (Executives file notice of proposed sale of common stock pursuant to rule 144; mega cap tech names lower on tariff news)
• AMZN -6.1% (mega cap tech names lower on tariff news)
• TSLA -5.9% (CEO Elon Musk denies report that he will soon leave role in government; mega cap tech names lower on tariff news)
• NVDA -5.6% (mega cap tech names lower on tariff news)
• HVT -5.2% (in sympathy with RH earnings and downbeat guidance)
• LCID -5% (prices $1.0 bln of 5.00% convertible senior notes due 2030)
• META -4.6% (mega cap tech names lower on tariff news)
• TTI -4.6% (announces withdrawal of investor group nominees)
• STN -4% (to acquire Page)
• GOOG -2.9% (mega cap tech names lower on tariff news)
• MSFT -2.5% (mega cap tech names lower on tariff news)
• UNIT -2.5% (stockholders approve merger with Windstream)
• PCAR -2.1% (CFO to retire)
• GETY -1.7% (GETY and SSTK receive DOJ request for additional info on merger)
• ONC -1.7% (announced the discontinuation of its clinical development program for ociperlimab (BGB-A1217), an anti-TIGIT antibody, as a potential treatment for lung cancer)